Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C
Adagrasib plus cetuximab was not cost-effective compared to adagrasib monotherapy as a late-line treatment for advanced or metastatic CRC patients with mutated KRAS<sup>G12C</sup> in the USA.
Authors
- Yao Jin
- Shangwei Guan
- Yao Yao (ORCID: https://orcid.org/0000-0003-1116-9461)
- Ruihong Yao
- Tong Liu (ORCID: https://orcid.org/0000-0001-9234-1328)
- Teng Xue
- Mei Dong (ORCID: https://orcid.org/0000-0002-7482-1499)
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Russian State Agrarian Correspondence University (RU)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1080/14737167.2025.2521439
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Natural Science Foundation of Heilongjiang Province